A recently published study introduces the PIPEDREAM model, using aggregated historical data from the pharmaceutical industry between 1997 and 2007. It highlights just how challenging and intricate the clinical research process can be. 📊
At each stage of development, decision-makers face a difficult balance:
✅ Advancing safe and effective medicines,
❌ While quickly and cost-effectively filtering out ineffective or unsafe candidates.
When this balance falters, critical decision errors occur:
❌ False positives: ineffective drugs that advance, only to fail later — wasting time and resources.
❌ False negatives: promising drugs that are terminated too early — missing life-saving opportunities.
🔎 Key findings from the study:
➡️ False positive rates are high in early phases.
➡️ False negative rates peak in Phase 2.
➡️ In Phase 3, there are signs of progression-seeking behavior, with more molecules pushed forward than expected.
This study underscores a vital truth: clinical research requires not only science but also deep expertise and precision planning.
That’s why partnering with a seasoned CRO is essential. At BiTrial, we leverage decades of experience to help our clients design, manage, and execute clinical trials with precision — reducing costly errors and driving projects to success.
🌐 Discover how BiTrial can support your next clinical trial! Get in touch with us!
📑full study: https://lnkd.in/d_xGBiY8